Peculiarity of recovery of the hypothalamic–pituitary–gonadal (HPG) axis, in men after using androgenic anabolic steroids

Cover Page
  • Authors: Lykhonosov M.P.1, Babenko A.Y.2,3, Makarin V.A.4, Fedotov Y.N.4
  • Affiliations:
    1. Pavlov First Saint Petersburg State Medical University
    2. Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
    3. Almazov National Medical Research Centre, St. Petersburg, Russia
    4. University hospital of Saint-Petersburg State University, St. Petersburg, Russia
  • Issue: Vol 66, No 1 (2020)
  • Pages: 104-112
  • Section: Reproductive Endocrinology
  • URL: https://probl-endojournals.ru/probl/article/view/12223
  • DOI: https://doi.org/10.14341/probl12223
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


BACKGROUND: Spontaneous recovery of the hypothalamic–pituitary–gonadal (HPG) axis after cessation of testosterone replacement therapy or after male contraception may take up to 24 months. There is insufficient data on the duration of recovery of HPG axis after abuse of androgenic anabolic steroids (AAS). AAS users use post-cycle therapy (PCT) to restore HPG axis, the effectiveness of which is unknown and needs further investigation.

AIMS: To evaluate the recovery of HPG axis in men, AAS users, after a 3-month of cessation of their use and after PCT.

METHODS: An observational, single-center, prospective, sampling, open, uncontrolled study was conducted among male AAS users. While using of AAS and 3 months after the refusal of their administration and PCT, the clinical symptoms of hypogonadism were evaluated, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (Tt), prolactin, estradiol, inhibin B, thyroid-stimulating hormone (TSH) were determined. The scheme of rehabilitation therapy was the same and did not change throughout the study. Recovery criteria: Tt >3.4 ng/ml and LH >1.24 mIU/ml. The study was conducted from January to August 2019. Fisher’s exact test, Mann-Whitney U-test, and Spearman’s rank correlation coefficient were used. The differences were considered statistically significant at p<0.05.

RESULTS: The study included 44 men, their age 29 years [27.75; 34], the duration of the use of AAS is 6 months [3.52; 7]. During the use of AAS: LH 0.2 mIU/ml [0.04; 0.47], Tt — 4.34 ng/ml [1.05; 8.81]. In this group, the number of men with a LH level <1.24 mIU / ml was 84% (n=37) and Tt <3.4 ng/ml was 47.7% (n=21). After 3 months, the LH level reached 4.12 mIU/ml [2.58; 5.84], Tt — 4.55 ng/ml [3.76; 6.24]. At the same time, the level of Tt <3.4 ng/ml remained in 20.5% (n=9), and LH <1.24 mIU/ml in 4.5% (n=2) men. According to the level of recovery of LH and Tt, patients were divided into two groups: with satisfying (n=35; 79.5%) and poor (n=9; 20.5%) recovery. A clear correlation was established between the duration of use (-0.857; p<0.0001), the amount (-0.443; p=0.003), the dose (-0.7825; p<0.0001), the type of AAS (-0.698; p<0.0001) and testosterone level recovery. A correlation between inhibin B and Tt (0.418; p=0.005) was revealed.

CONCLUSIONS: A three-month refusal to use AAS with PCT led to the restoration of HPG axis a in 79.5% of the volunteers. In 20.5% of cases, recovery did not occur. The negative effect of the duration of use, the number of simultaneously administered drugs, their dose and type of AAS on the restoration of HPG axis was established. The level of inhibin B may serve as a marker for the restoration of spermatogenic epithelium.


Full Text

Restricted Access

About the authors

Mykola P. Lykhonosov

Pavlov First Saint Petersburg State
Medical University

Author for correspondence.
Email: likhonosov.np@gmail.com
ORCID iD: 0000-0001-6460-5226
SPIN-code: 2102-5358

Russian Federation, 6/8 L’va Tolstogo street, St. Petersburg, 197022 Russian Federation

MD, PhD student Pavlov First Saint Petersburg State
Medical University

Alina Y. Babenko

Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia;
Almazov National Medical Research Centre, St. Petersburg, Russia

Email: alina_babenko@mail.ru
ORCID iD: 0000-0002-0559-697X
SPIN-code: 9388-1077

Russian Federation, 6/8 L’va Tolstogo street, St. Petersburg, 197022 Russian Federation; 2 Akkuratova street, St. Petersburg 197341

MD, associate professor of the faculty of therapy with a course of endocrinology, cardiology and functional diagnostics named after G.F. Langa with the clinic of the First St. Petersburg State Medical University named after Acad. I.P.Pavlova Ministry of Health of Russia

Viktor A. Makarin

University hospital of Saint-Petersburg State University, St. Petersburg, Russia

Email: mvaviktor@mail.ru
ORCID iD: 0000-0003-1710-8045
SPIN-code: 8885-2085

Russian Federation, Universitetskaya nab., 7/9, St. Petersburg, 199034

MD, PhD, Head of the medical and diagnostic complex for Korablestroitelej University hospital of Saint-Petersburg State University

Yury  N. Fedotov

University hospital of Saint-Petersburg State University, St. Petersburg, Russia

Email: 6762525@gosmed.ru
ORCID iD: 0000-0003-0445-9428

Russian Federation, Universitetskaya nab., 7/9, St. Petersburg, 199034

MD, PhD, Professor, First Vice-Rector for Medical Activities, Director of the N. I. Pirogov Clinic for High Medical Technologies

References

  1. McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian J Androl. 2016;18(3):373–380. doi: https://doi.org/10.4103/1008-682x.173938.
  2. Дедов И.И., Мельниченко Г.А., Роживанов Р.В., Курбатов Д.Г. Рекомендации по диагностике и лечению гипогонадизма (дефицита тестостерона) у мужчин. Проект // Проблемы эндокринологии. — 2015. — Т.61. — №5. — C. 60–71. [Dedov II, Mel’nichenko GA, Rozhivanov RV, Kurbatov DG. The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project. Problems of Endocrinology. 2015;61(5):60–71. (In Russ).] doi: https://doi.org/10.14341/probl201561560-71.
  3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi: https://doi.org/10.1210/jc.2018-00229.
  4. El Osta R, Almont T, Diligent C, et al. Anabolic steroids abuse and male infertility. Basic Clin Androl. 2016;26:2. doi: https://doi.org/10.1186/s12610-016-0029-4.
  5. Лихоносов Н.П., Бабенко А.Ю. Медицинский аспект использования анаболических андрогенных стероидов у мужчин, посещающих тренажерные залы Санкт-Петербурга // Проблемы эндокринологии. — 2019. — T.65. — №1. — C. 19–30. [Lykhonosov MP, Babenko AY. The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint-Petersburg. Problems of Endocrinology. 2019;65(1):19–30. (In Russ).] doi: https://doi.org/10.14341/probl9832.
  6. Park HJ. Anabolic steroid-induced hypogonadism: a challenge for clinicians. J Exerc Rehabil. 2018;14(1):2–3. doi: https://doi.org/10.12965/jer.1836036.018.
  7. Zhu ZG, Zhao ZG, Pang QY, et al. Predictive significance of serum inhibin B on testicular haploid gamete retrieval outcomes in nonobstructive azoospermic men. Asian J Androl. 2019;21(2):137–142. doi: https://doi.org/10.4103/aja.aja_94_18.
  8. Tatem AJ, Beilan J, Kovac JR, Lipshultz LI. Management of anabolic steroid-induced infertility: novel strategies for fertility maintenance and recovery. World J Mens Health. 2020;38(2):141–150. doi: https://doi.org/10.5534/wjmh.190002.
  9. Приказ Минздрава России от 09.11.2012 № 780н «Об утверждении стандарта первичной медико-санитарной помощи при гипогонадизме». [Order of the Ministry of Health of the Russian federation № 780n «Ob utverzhdenii standarta pervichnoi mediko-sanitarnoi pomoshchi pri gipogonadizme» dated 09.11.2012. (In Russ).] Доступно по: http://base.garant.ru/70304310/. Ссылка активна на 12.02.2020.
  10. Bland M. An introduction to medical statistics. 3rd. ed. Oxford: Oxford University Press; 2000. P. 335–347.
  11. Collins R. The war on anabolic-androgenic steroids. In: Van de Ven K, Mulrooney KJ, McVeigh J, editors. Human enhancement drugs. London: Routledge; 2019. P. 264–279. doi: https://doi.org/10.4324/9781315148328-19.
  12. Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247–1264. doi: https://doi.org/10.1517/14656566.2014.913022.
  13. Christou MA, Tigas S. Recovery of reproductive function following androgen abuse. Curr Opin Endocrinol Diabetes Obes. 2018;25(3):195–200. doi: https://doi.org/10.1097/med.0000000000000406.
  14. Kumanov P, Nandipati K, Tomova A, Agarwal A. Inhibin B is a better marker of spermatogenesis than other hormones in the evaluation of male factor infertility. Fertil Steril. 2006;86(2):332–338. doi: https://doi.org/10.1016/j.fertnstert.2006.01.022.
  15. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23(6):793–800. doi: https://doi.org/10.1016/j.beem.2009.08.003.

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 355

PDF (Russian) - 0

Cited-By


PlumX

Dimensions


Copyright (c) 2020 Lykhonosov M.P., Babenko A.Y., Makarin V.A., Fedotov Y.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies